EUCTR2008-000759-91-IT进行中（未招募）不适用
Sorafenib plus paclitaxel metronomic chemotherapy in adreno-cortical-carcinoma patients progressing after 1st or snd line cytotoxic chemotherapy - PAXO
AZIENDA OSPEDALIERA S. LUIGI GONZAGA0 个研究点目标入组 25 人开始时间: 2008年7月28日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- histologically confirmed diagnosis of ACC
- •- locally advanced or metastatic disease not amenable to radical surgery resection
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- history of prior malignancy
- •- severe renal insufficiency
研究者
相似试验
Unknown
2 期
Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer PatientsAdrenocortical CarcinomaNCT00786110University of Turin, Italy30
已完成
2 期
Investigating the role of targeted therapy Sorafenib - the Fms-like tyrosine kinase 3 (FLT3) inhibitor, in combination with intensive chemotherapy, for previously untreated adult patients with Acute Myeloid Leukaemia (AML) with FLT3 mutations. A Phase II randomised placebo-controlled multi-centre studyPreviously untreated adult acute myeloid leukaemia (AML) with FLT3-ITD mutation.Cancer - Leukaemia - Acute leukaemiaACTRN12611001112954eukaemia Foundation of Australia98
招募中
2 期
Concurrent paclitaxel and carboplatin-based chemoradiotherapy for stage III or IVA cervical cancer with renal dysfunctioCervical cancerJPRN-jRCTs031180165Imai Yuichi32
已完成
1 期
Combination chemotherapy of sorafenib and S-1 in patients with advanced hepatocellular carcinoma: phase I trialHepatocellular carcinomaJPRN-UMIN000002418Kanazawa University Hospital21
进行中（未招募）
2 期
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell CancerMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Squamous Cell Carcinoma of the HypopharynxMetastatic Squamous Cell Carcinoma of the LarynxMetastatic Squamous Cell Carcinoma of the Oral CavityMetastatic Squamous Cell Carcinoma of the OropharynxRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oral Cavity Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaNCT00494182M.D. Anderson Cancer Center48